Immutep Limited Share Price
Stocks
IMM
AU000000IMM6
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Australian S.E.
05:06:12 19/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.0230 AUD | 0.00% |
|
-14.81% | -94.46% |
| 09-17 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
| Market Cap | 33.9M 23.58M 20.96M 19.43M 17.68M 33.36M 2.24B 234M 91.58M 1.17B 88.51M 86.63M 3.72B | P/E 2027 * |
-1.35x | P/E 2028 * | -2.09x |
|---|---|---|---|---|---|
| Enterprise Value | -20.7M -14.41M -12.81M -11.87M -10.8M -20.38M -1.37B -143M -55.94M -713M -54.07M -52.91M -2.27B | EV / Sales 2027 * |
-5.18x | EV / Sales 2028 * | 0.02x |
| Free-Float |
96.87% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| IMM | Delayed | |
Tradegate
| YP1B | Real-time | |
|
OTC Markets
| PRRUF | Delayed | |
|
Boerse Muenchen
| YP1B | Real-time | |
|
Deutsche Boerse AG
| YP1B | Delayed | |
|
Börse Stuttgart
| YP1B | Delayed |
| 1 week | -14.81% | ||
| Current month | -32.35% | ||
| 1 month | -42.50% | ||
| 3 months | -54.00% | ||
| 6 months | -65.67% | ||
| Current year | -94.46% |
| 1 week | 0.02 |  | 0.03 |
| 1 month | 0.02 | | 0.04 |
| Current year | 0.02 | | 0.47 |
| 1 year | 0.02 | | 0.47 |
| 3 years | 0.02 | | 0.48 |
| 5 years | 0.02 | | 0.71 |
| 10 years | 0.02 | | 0.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 08/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 28/02/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Russell Howard
CHM | Chairman | 76 | 16/11/2017 |
Marc Voigt
BRD | Director/Board Member | 53 | 08/07/2014 |
Frédéric Triebel
BRD | Director/Board Member | 71 | 12/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Exercice | Director | -388,889 | 0.0264% | ||
| 01/10/26 | Exercice | Director | 388,889 | 0.0264% | ||
| 18/03/26 | Other | Chief Technology Officer | 14,224,374 | 0.9652% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -14.81% | -92.07% | -91.64% | 23.58M | |
| -6.60% | -8.56% | +49.38% | +64.90% | 65B | |
| +0.03% | +5.56% | +9.10% | +75.22% | 51.2B | |
| -4.09% | -0.11% | +2.22% | +55.67% | 51.19B | |
| -1.53% | +2.70% | +30.48% | +41.25% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +120.28% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +483.48% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +56.32% | 33.24B | |
| -0.90% | -10.49% | +37.09% | +1.80% | 25.2B | |
| -1.07% | +2.33% | +19.43% | +20.40% | 22.5B | |
| Average | -1.49% | -1.47% | +31.76% | +82.77% | 37.24B | |
| Weighted average by Cap. | -2.20% | -0.50% | +44.24% | +103.64% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4M 2.78M 2.47M 2.29M 2.09M 3.94M 264M 27.56M 10.81M 138M 10.45M 10.22M 439M | 3M 2.09M 1.86M 1.72M 1.56M 2.95M 198M 20.67M 8.11M 103M 7.83M 7.67M 330M |
| Net income | -26.1M -18.16M -16.14M -14.96M -13.61M -25.69M -1.72B -180M -70.51M -899M -68.16M -66.7M -2.87B | -30.47M -21.2M -18.85M -17.47M -15.89M -29.99M -2.01B -210M -82.33M -1.05B -79.58M -77.88M -3.35B |
| Net Debt | -54.6M -37.99M -33.77M -31.3M -28.48M -53.74M -3.61B -376M -148M -1.88B -143M -140M -6B | -33.83M -23.54M -20.93M -19.4M -17.65M -33.3M -2.23B -233M -91.41M -1.17B -88.35M -86.47M -3.72B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/10/26 | A$0.0230 | 0.00% | 3,041,399 |
| 16/10/26 | A$0.0230 | 0.00% | 3,393,799 |
| 15/10/26 | A$0.0230 | -8.00% | 11,987,136 |
| 14/10/26 | A$0.0250 | -3.85% | 9,183,279 |
| 13/10/26 | A$0.0260 | -3.70% | 5,288,830 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMM Stock
Select your edition
All financial news and data tailored to specific country editions
